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Abstract
Introduction: Joint damage in haemophilia often requires surgical correction. How-
ever, the surgery effect on bleeding rates and other clinical joint outcomes can be
unclear.
Aim: To investigate the effects of joint surgery on joint annualized bleeding rates
(JABRs) and physical health outcomes in patients with haemophilia A undergoing N8-
GP prophylaxis.
Methods: Patients in the pathfinder 2 trial received N8-GP prophylaxis, enrolling
in the pathfinder 3 trial for indicated surgery. Patients returned to pathfinder two
post-surgery, continuing N8-GP prophylaxis until end-of-trial. JABRs were calculated
from bleeding across all joints for pre-surgery (immediately before surgery) and post-
surgery (to pathfinder 2 study end) periods. Joint-health-related outcomes were
derived from patient records.
Results: Data (41 joint surgeries; n = 30) were analysed statistically using datamin-
ing and descriptively. Pre-surgery mean JABR was higher in patients who later were
operated than in 146 non-operated patients (p = .004). In operated patients, mean
JABR decreased from 1.33 pre-surgery to .37 post-surgery (p = .011). In all but three
patients, JABR improved or remained the same post-surgery. In the three patients
whose JABR remained at one (all with multiple joint arthropathy), post-surgery bleeds
were mostly at non-operated sites. Two of the three patients whose JABR increased
post-surgery had undergone surgery for reasons unlikely to improve JABR. Mobility
parameters often improved in patients whose JABR remained at zero.
Conclusion: Patients with haemophilia treated with N8-GP prophylaxis benefit from
surgeries. However, this analysis could not differentiate the relative contributions of
surgical interventions and prophylactic treatment to the improvement of JABR.
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1 INTRODUCTION
Patients with haemophilia A often experience recurrent joint bleed-
ing; as a result, haemophilic arthropathy can develop,1 which may
require surgery. For patientswith haemophilia A requiring orthopaedic
surgery, the World Federation for Haemophilia recommends, in addi-
tion to factor replacement therapy, close monitoring and careful pain
management in the post-operative period.1 The aim of surgery is to
improve wellbeing and quality of life of patients with haemophilia A1;
however, it is important that patients and their haemophilia care team
have realistic expectations about post-surgery outcomes.2 Under-
standing the effects of surgery on bleeding rates, pain and mobility
helps facilitate these discussions.
Turoctocog alfa pegol (N8-GP; Novo Nordisk A/S, Bagsvaerd, Den-
mark) is an extended half-life human recombinant factor VIII (FVIII)
product3; its efficacy and safety were extensively studied in the
pathfinder clinical trial programme.4 The pivotal pathfinder 2 trial
(N = 186) investigated the efficacy and safety of N8-GP prophylaxis
in adults and adolescents (≥12 years of age) with severe haemophilia
A previously treated with ≥150 exposure days of any FVIII product.
It found that patients treated with a prophylaxis regimen of N8-GP
every fourth day achieved an observed median annualized bleeding
rate (ABR) of .84. During the sixth year of pathfinder 2, 64%of patients
experienced no bleeds.5
Pathfinder 3 (N= 36; 35 underwent 49major surgeries) specifically
investigated the efficacy and safety of N8-GP in a subgroup of patients
frompathfinder2who requiredmajor surgeryandhad receivedat least
five doses of N8-GP, and has been described previously.4,6,7 During
surgery, haemostasis was rated excellent or good in 96% of surgeries;
therewere four joint bleeds in the post-operative period, all wereman-
aged successfully with N8-GP (except in one case where haemostasis
efficacy post-bleedwas not evaluated).4,7 After pathfinder 3 treatment
completion, patients returned to pathfinder 2 and continued N8-GP
prophylaxis until end-of-trial.6
The aim of this post hoc analysis was to evaluate the effect of joint
surgery followed byN8-GP prophylaxis on clinical outcomes restricted
to joints (joint ABR [JABR]) and patient-reported outcomes (PROs)
in patients with haemophilia A. This evaluation was performed by
applying datamining techniques retrospectively to the final results of
the pathfinder 2 and 3 clinical trials and analysing the resulting data
descriptively.
2 MATERIALS AND METHODS
2.1 Research questions and analyses undertaken
Three analyses were performed to elucidate the outcomes of elective
orthopaedic surgery followed by N8-GP prophylaxis in patients with
haemophilia A. JABR and physical health outcomes were assessed to
address the following exploratory scientific questions:
∙ Question 1: How does the JABR in patients who did not
require surgery on their joints compare with the pre-surgery
JABR in the operated patients? (Addressed using a datamining
analysis),
∙ Question 2: Does JABR in patients whose joints were operated on
change from pre-surgery to post-surgery, with N8-GP prophylaxis
throughout? (Addressed using a datamining analysis),
∙ Question 3: Why, in some patients, does JABR either not improve
or worsen from pre-surgery to post-surgery? (Addressed using a
descriptive analysis).
Where datamining was used, we conducted retrospective,
exploratory interrogation of multiple pre-existing data sources,
applying statistical analysis to answer specific scientific questions.
2.2 Data source
Data from adult and adolescent patients enrolled in the multina-
tional pathfinder 2 trial (NCT01480180), who subsequently joined
the pathfinder 3 trial (NCT01489111) to undergo their elective
orthopaedic surgery and then rejoined pathfinder 2, were considered
for this post hoc datamining analysis. The design of the pathfinder 3
trial (including N8-GP surgical protocol and assessment details) has
been described elsewhere.6,7 The multinational pathfinder 3 trial pro-
duced a cohort of patients who were operated for major surgery and
whose JABR outcomes were known. This cohort was used in this post
hoc analysis. The analysis only concerned the period during which the
patients received prophylaxis with N8-GP every fourth day – periods
when patients received on-demand treatment were excluded. Non-
joint surgeries were also excluded.
2.3 Statistical analyses
The statistical analyses described below were developed to compare
bleed rates across strata of clinical relevance (e.g., bleed location) and
across various time points (e.g., pre- and post-surgery). Unless already
available in the trial data collected, bleed rates per strata were com-
puted based on the number of bleeds during the defined relevant time
periods.
Analytical assessments were undertaken to determine the JABR
of operated and non-operated patients. Pathfinder 2 and pathfinder
3 data were combined in a single dataset structure that would allow
a statistical analysis of the chosen clinical outcome of interest, ABRs
and, in particular, JABR. ABRs and JABRs were calculated at different
time points relative to the surgery. JABRs were calculated collectively
across all reported joint locations; therefore, JABRs are not specific to
the location of joint surgery.
The datamining model calculated ABRs and JABRs based on the
number of bleeds reported between the relevant time point and 365
days prior; where a full 365 days of prior data were not available or
would overlap with an earlier surgery period, the period of available
qualifying bleed count data was used and scaled to yield an ABR that
could be fairly compared with other calculated ABRs. To evaluate the
impact of surgery on individual patients in pathfinder 3, ABRs and
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TABLE 1 Baseline characteristics and bleed frequency in operated patients
Baseline characteristicsa Prophylaxisb (n= 22) On-demandc (n= 8) Total (N= 30)
Age, mean (SD) 35.5 (13.5) 43.2 (11.1) 37.6 (13.2)
BMI, mean (SD) 25.2 (4.6) 26.3 (4.9) 25.5 (4.7)
ABR
Mean (SD) 4.6 (5.7) 30.5 (31.2) 11.5 (19.8)
Median (IQR) 2.5 (1.0–5.8) 19.5 (11.2–34.8) 3.5 (2.0–12.0)
Pre-surgery JABR rangeb
0 to< 1, n (%) 12 (54.5) 3 (37.5) 15 (50.0)
1 to< 3, n (%) 7 (33.3) 4 (50.0) 11 (36.7)
3 to< 20, n (%) 3 (13.6) 1 (12.5) 4 (13.3)
Abbreviations: ABR, annualized bleeding rate; BMI, bodymass index; IQR, interquartile range; JABR, joint annualized bleeding rate; SD, standard deviation.
aOne patient counted in the calculations for the baseline characteristics had no surgery information in their patient records, but PRO outcomes were
recorded.
bThe ‘prophylaxis’ and ‘on-demand’ subgroups refer to treatment regimens before entry into pathfinder 2; after study entry, all 30 patients were on prophy-
laxis (28 patients started the pathfinder 2 study on prophylaxis while two patients started on-demand but switched to prophylaxis during the study).
cCounts presented based on JABR status before first surgery (some patients underwentmultiple surgeries).
JABRs were calculated at three specific time points: (1) baseline ABR
as the self-reported historical ABRs collected at the start of pathfinder
2; (2) pre-surgery JABR as imputed from the pre-surgery period; (3)
post-surgery JABR as the outcome JABR at the end of pathfinder 2.
For each joint surgery, the number of days of prophylacticN8-GP treat-
ment before (since treatment initiation) and after (until trial comple-
tion) surgery were calculated. Pre-surgery JABR ranges (0– < 1, 1–
< 3 and 3– < 20) were established and patients stratified according to
prophylactic or on-demand treatment. The ranges were chosen to pro-
vide clinical context to the data. Pre-surgery JABRof operated patients
was computed from the number of days of N8-GP prophylaxis expo-
sure for each of the 41 applicable surgeries (i.e., exposure in the 365
days prior, if available, as described above). For comparison purposes,
median JABRs were calculated for corresponding treatment durations
from the non-operated patient cohort who started pathfinder 2 on a
prophylaxis regimen of N8-GP every fourth day (n = 146) at equiva-
lentN8-GPexposuredurations to the41 surgeries among theoperated
cohort.
Pre-surgery versus post-surgery JABRs in operated patients were
compared with non-parametric Mann-Whiney U testing (pre-surgery
JABRs based on number of surgeries; post-surgery JABRs based
on number of patients). Pre-surgery JABRs in non-operated versus
operated patients were compared using non-parametric Wilcoxon
signed-rank testing (pairwise comparison between non-operated vs.
operated group); pre-surgery JABR of the non-operated cohort was
calculated by averaging the JABRs of this cohort at the 41 surgery time
points.
2.4 Descriptive analysis
A qualitative assessment of the clinical characteristics of patients who
underwent surgeries in pathfinder 3 was undertaken and a descrip-
tive analysis generated. Patients were classified according to whether
their JABR improved, did not change, or worsened when comparing
pre-surgery with study outcome values. Records of individual patients
were examined to evaluate their medical history, identifying specific
events and circumstances contributing to bleeding patterns. Individual
patient responses to three questions relevant to physical health from
the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-
QoL) AU1.0 were assessed before and after surgery, and responses to
these questions (‘In the past 4weeks, I had pain inmy joints’, ‘In the past
4 weeks, it was painful for me to move’, ‘In the past 4 weeks, I had dif-
ficulty walking as far as I wanted to’) extracted. Pre-surgery, responses
were collected at pathfinder 3 screening; post-surgery responseswere
collected at the first visit after return into pathfinder 2.
3 RESULTS
3.1 Baseline characteristics
Data from 41 joint surgeries in 30 patients were analysed statistically
and descriptively. Patients received N8-GP prophylaxis for a mean of
702.0 days pre-surgery (standard deviation [SD], 547.5 days; range:
17–2017days) and1180days post-surgery (SD, 572.5 days; range: 54–
1938 days). The baseline characteristics and bleed frequency for oper-
ated patients included in the analysis are shown in Table 1. Twenty-two
patients were on a prophylactic regimen before entering pathfinder
2; eight received on-demand treatment before pathfinder 2. In the
present analysis, prophylactic treatment with N8-GP was undertaken
for< 365 days in 14 patients (14 surgeries); of these 14 patients, seven
(seven surgeries) had a JABR of 0 both pre-surgery and post-surgery.
A pre-surgery JABR of 0– < 1 was common for patients treated with
prophylaxis (n = 12, 54.5%), whereas only 37.5% of patients (n = 3)
treated on-demand had a JABR of 0–< 1.
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F IGURE 1 Mean JABR in pre-surgery and post-surgery periods and in non-operated patients in a pre-surgery-equivalent period. Figure shows
mean JABR, to give context to the data and the differences found by the statistical analyses; median JABR for all three groupswas 0. All 30 patients
in the operated cohort (pre-surgery and post-surgery data) were on prophylaxis with N8-GP every 4 days (28 patients started the pathfinder 2
study on prophylaxis, while two patients started on-demand but switched to prophylaxis during the study). Data regarding surgery was not
available in the records of one patient; however, PRO data were recorded and therefore this patient has been counted in the operated cohort. All
146 patients in the non-operated cohort started themain phase of pathfinder 2 onN8-GP prophylaxis every 4 days. †Wilcoxon signed-rank test.
‡Mann-Whitney U test. §Mean JABR of the non-operated cohort was calculated from periods of N8-GP exposure equivalent to the 41 surgeries.
Median JABRwas calculated using the same periods. JABR, joint annualized bleeding rate; N8-GP, turoctocog alfa pegol
TABLE 2 Numbers of patients and surgeries in each JABR outcome group
Post-surgery versus pre-surgery JABR
Improved Remained at 0 Remained at 1 Worseneda Total
Number of patients 13 13bc 3b 3 30
Pre-surgery JABR rangesd
0 N/A 12 N/A 3 15
1 to< 3 9 N/A 2 0 11
3 to< 20 4 N/A N/A 0 4
Number of surgeries 17 18 3 3 41
aOf the three patients whose JABRworsened, all had long-standing arthropathy/chronic pain; one patient was operated for implant pain and another patient
was operated for bilateral trigger thumbs.
bOne patient in this groupwas not counted in the stratification by pre-surgery JABR ranges, as they had a previous surgery where JABR improved.
cOne patient in this group had no surgery information in their patient records, but PRO outcomeswere recorded.
dCounts presented based on JABR status after first surgery (some patients underwentmultiple surgeries).
Abbreviations: JABR, joint annualized bleeding rate; N/A, not applicable.
3.2 Datamining analysis of JABR in operated
patients
In patients who were operated, there was a significant decrease in
JABR between pre-surgery and post-surgery (mean JABR 1.33 vs. .37;
p = .011; median JABR 0 vs. 0; Figure 1). Pre-surgery JABRwas signif-
icantly higher in operated than in non-operated patients over an equiv-
alent period (mean JABR 1.33 vs. .33; p = .004; median JABR 0 vs.
0; Figure 1). Data regarding surgery was not available in one patient’s
records; however, PRO data were recorded and therefore this patient
has been counted in the operated cohort.
3.3 Descriptive analysis of JABR post-surgery
3.3.1 Patients whose JABR improved or remained
the same
In most operated patients, post-surgery JABR improved or stayed the
same versus pre-surgery (n = 27; Table 2). Most of these patients
had a pre-surgery JABR of < 3, but four patients who improved had
a pre-surgery JABR of ≥3. Patients whose JABR improved from pre-
surgery to post-surgery (17 surgeries; n = 13) were operated on for
the following reasons: arthropathy and/or pain in joint (15 surgeries;
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TABLE 3 Patient profiles for patients whose JABR remained at 1 or worsened post-surgery
JABR remained at 1 JABRworsened
Patient profile 1 2 3 4 5 6
Age, years 37 66 25 20 15 63
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24 versus 1 8 versus 1 3 versus 1 3 versus 3 2 versus 4 1 versus 2
Pre-surgery versus
post-surgery JABR
1 versus 1 1 versus 1 1 versus 1 0 versus 2 0 versus 3 0 versus 2
Abbreviations: ABR, annualized bleeding rate; JABR, joint annualized bleeding rate; PRO, patient-reported outcome.
aThis prosthesis was removed due to implant pain; new prosthesis was not added.
n = 12) and bone problems (fracture of femoral neck, left ankle talo-
calcaneal posterior coalition and in situ calcaneo-talar fixation for left
ankle talocalcaneal posterior coalition; two surgeries; n = 2). One
patient was operated for two different indications: chronic pain and
a bone anomaly (patient 2 in Supplementary Appendix Table 1). In
15 out of these 17 surgeries, JABR decreased to zero; in the remain-
ing two surgeries, JABR decreased to one (Supplementary Appendix
Table 1).
Themajority of patientswhose JABRwas zero both pre-surgery and
post-surgery were operated on for arthropathy (11 surgeries; n = 9).
Other indications for surgery in this group included prosthesis issues
(five surgeries; n = 3) and Charcot ankle (one surgery; n = 1). One
patient in this group was not operated on. One patient was counted
twice due to two surgeries for different indications.
In the subgroup of patients who were operated for arthropathy
and whose JABR remained at zero, all had long-standing haemophilic
arthropathy. There were only three bleeding episodes at the operated
site; in all other instances, any bleeding was at non-operated sites.
All patients whose JABR was stable at one had multiple joint
arthropathy, and post-surgery bleeds were mostly at non-operated
sites.
3.3.2 Patients whose JABR worsened
In patients whose JABR worsened from pre-surgery to post-surgery
(n = 3), JABR increased from 0 (pre-surgery) to 2–3 (post-surgery).
All patients in this group had a pre-surgery JABR of 0. Two of the three
patients whose JABR increased were operated for prosthetic pain and
bilateral trigger thumbs (patient profiles 4 and5 in Table 3). The patient
who was operated for arthropathy (patient profile 6, Table 3) experi-
enced joint or muscle bleeding in the right leg (knee, calf and thigh) 23
days after surgery; this was likely due to insufficient FVIII substitution,
and FVIII dosewas subsequently increased;mobility-related outcomes
improved in this patient.
3.4 PRO outcomes, post-surgery
Joint pain (from the Haem-A-QoL PRO questionnaire) most often
remained the same, while mobility and pain during movement most
often improved, in patients whose JABR was 0 pre-surgery and post-
surgery (Table 4). A similar pattern was found when Haem-A-QoL
PRO scores were analysed in patients whose JABR did not improve
post-surgery (i.e., remained at 0, remained at 1, or worsened) (Sup-
plementary Appendix Table 2). In this set of patients, following seven
surgeries the PRO score associated with pain in joints improved,
following four surgeries the PRO score worsened and following 11
surgeries the PRO score stayed the same. Following 14 surgeries,
the PRO score associated with movement-related pain improved,
following five surgeries it worsened and following three surgeries it
stayed the same. Following 12 surgeries the PRO score associatedwith
difficulty walking improved, following five surgeries it worsened and
following six surgeries it stayed the same.
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TABLE 4 Effect of surgery on PRO scores in patients whose JABR













Pain in the joints 6 9 2 1
Painful to move 13 1 4 –
Difficulty to walk as far
as wanted
10 4 4 –
Joint-health-related PROs were based on responses to the Haem-A-QoL
AU1.0 before (at the pathfinder 3 screening visit) and after (first visit after
return into pathfinder 2) surgery, as recorded in patient records. Questions
in the Haem-A-QoL AU1.0: ‘In the past 4 weeks, I had pain in my joints’,
‘In the past 4 weeks, it was painful for me to move’, ‘In the past 4 weeks, I
had difficulty walking as far as I wanted to’. Haem-A-QoL scoring: 1= never
experience this, 2= seldom experience this, 3= sometimes experience this,
4= often experience this, 5= experience this all of the time.
Abbreviations: Haem-A-QoL, Haemophilia Quality of Life Questionnaire for
Adults; JABR, joint annualized bleeding rate; N/A, not applicable; PRO,
patient-reported outcome.
4 DISCUSSION
This combined analysis of pathfinder 2 and 3 data permitted assess-
ment of joint bleeding and PROs after joint surgery in patients receiv-
ing continued N8-GP prophylaxis. JABR was significantly higher in
patients who had major joint surgery compared with a cohort from
pathfinder 2 not operated. The results from the pre- to post-surgery
analysis are reassuring, because JABR significantly declined follow-
ing surgery. Importantly, most patients included in this study had a
relatively low pre-surgery JABR. Furthermore, the descriptive analy-
ses provided insights into patients whose JABR did not improve. Most
patients whose JABR worsened were operated for indications such as
prosthetic pain and bilateral trigger thumbs, resolution of which may
not be expected to necessarily lead to improvement in long-standing
arthropathy and hence JABR. In patients whose JABR remained at 1,
post-surgerybleedsweremostly at non-operated locations,which indi-
cates that surgery may have improved joint pathology and decreased
bleeding in the affected joint. In all patients whose JABR did not
improve, particularly in thosewhose JABR remained at 0,Haem-A-QoL
PRO parameters indicated improvements in pain andmobility.
The main result of this study was the significant mean JABR
decrease between the pre-surgery and post-surgery periods in
patients receiving N8-GP prophylaxis. This is important because
repeated joint bleeds lead to synovitis and hyperplasia, ultimately
resulting in haemophilic arthropathy8; tertiary prophylaxis with a
recombinant FVIII, when compared with on-demand treatment, has
been shown to reduce bleeding and have positive effects on patients’
lives.9 In our analysis, reduced bleeding post-surgery may occur for
various reasons: improved joint function, better physiotherapy as part
of haemophilia management optimization, a temporary more seden-
tary lifestyle, or, in patients with total joint replacement, complete
removal of synovia from the joint. Regardless of the cause, decreased
post-surgery bleedingmay prevent the inflammatorymilieu character-
istic of haemophilic joints, thereby precluding further joint damage.
In this study, pre-surgery JABR was higher in operated patients
versus non-operated patients. Chronic pain and functional impair-
ment due to severe joint damage is a main reason to undergo major
orthopaedic surgery,1 hence a higher JABRwould be expected in oper-
ated patients.
In addition to JABR, post-surgery outcomes may be measured
through parameters such as changes in mobility impairment, current
health status and pain, which impact patients’ lives and have great clin-
ical relevance.10 The qualitative analysis of the clinical narratives and
patientprofiles presentedhere, in combinationwith the JABRanalyses,
elucidated whether our findings reflected clinical experience. These
results should be considered in the broader context for patients with
haemophilia A, who face challenges in their day-to-day lives due to
the musculoskeletal complications secondary to haemophilia.11 Our
study showed that in patients whose JABR improved post-surgery,
most had no post-surgery bleeds, and the rest had a JABR of 1. In
the context of important outcomes for patients’ lives, reductions in
bleeds and improvements in quality of life could be highly beneficial.
This study may indicate that, even in patients whose JABR remained
the same (at 0 or 1 pre- and post-surgery), other factors (e.g., decrease
in pain, improvements in mobility) could be contributing to a benefi-
cial effect of surgery and N8-GP prophylaxis. Our finding of improve-
ments in mobility-related scores is consistent with a PRO analysis of
pathfinder 2 data,12 inwhich adults showed improvements in thePhys-
ical Health domain of the Haem-A-QoL and parents of adolescents
showed improvements in the Haemophilia Quality of Life Question-
naire (although adolescents themselves did not).12 However, not all
patientswhose JABR remained the sameexperienced improvements in
these clinically relevant factors. This is supported by a previous study
showing that a higher degree of haemophilic arthropathy may be asso-
ciatedwith decreased quality of life (particularly in physical aspects).13
All patients whose JABR remained at 0 post-surgery had long-
standing arthropathy; therefore, examining mobility PRO outcomes
and pain was particularly relevant. The findings on these outcomes in
these patients were reassuring; however, an important caveat is the
small number of patients included, meaning generalizations should be
minimized. Studies with more patients are necessary to confirm our
findings.
All patients included in this analysiswere being treatedwithN8-GP;
therefore, our results were due to a combination of surgery and N8-
GP prophylaxis. However, this analysis was not designed to evaluate
the individual effects of surgery andN8-GP prophylaxis, or the relative
contribution of each to the beneficial effects observed in this study.
The first major limitation to these analyses was that it was not pos-
sible to determine the root cause for the reported outcomes, because
the effects of surgerywere supplemented by the effects of N8-GP pro-
phylaxis. The second was that the sample size available was too small
for statistical comparisons inmost cases. Some of the presented analy-
ses use averaged calculations (e.g., mean ABR), whichmay give an inac-
curate representation of the cohort because the mean is likely to be
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heavily influenced by magnitude and number of outliers, which dispro-
portionally affect it. Also, as this study was not designed to investigate
the causative factors for the improvements in JABR and PROs, these
findings should be interpreted with caution. Finally, pathfinder 3 was
a multicentre trial – there may have been some differences in surgi-
cal techniques/practices between sites and surgeons, but these differ-
ences were not systematically assessed.
5 CONCLUSION
Our results provide evidence that JABR significantly declined post-
surgery and, most often, pain and mobility parameters improved in
patients whose pre- and post-surgery JABR was zero. It is likely that
the beneficial effects observed in our study are a result of both surgery
and concurrent treatment with N8-GP prophylaxis. Our results there-
fore support the notion that patients with haemophilia A being treated
with N8-GP prophylaxis benefit from surgeries, as do those with low
pre-surgery JABRs.
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